Order Article Reprints

Tanimura K, Takeda T, Kataoka N, Yoshimura A, Nakanishi K, Yamanaka Y, Yoshioka H, Honda R, Uryu K, Fukui M, et al. First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. Cancers. 2023; 15(20):4988. https://doi.org/10.3390/cancers15204988

Tanimura, Keiko, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu, Mototaka Fukui, and et al. 2023. "First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study" Cancers 15, no. 20: 4988. https://doi.org/10.3390/cancers15204988

Tanimura, K., Takeda, T., Kataoka, N., Yoshimura, A., Nakanishi, K., Yamanaka, Y., Yoshioka, H., Honda, R., Uryu, K., Fukui, M., Chihara, Y., Takei, S., Kawachi, H., Yamada, T., Tamiya, N., Okura, N., Yamada, T., Murai, J., Shiotsu, S., ... Takayama, K. (2023). First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. Cancers, 15(20), 4988. https://doi.org/10.3390/cancers15204988